None
Quote | Y-mAbs Therapeutics Inc. (NASDAQ:YMAB)
Last: | $12.16 |
---|---|
Change Percent: | -0.26% |
Open: | $11.62 |
Close: | $12.16 |
High: | $12.27 |
Low: | $11.355 |
Volume: | 227,270 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Y-mAbs Therapeutics Inc. (NASDAQ:YMAB)
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-01 16:14:37 ET More on Y-mAbs Therapeutics Y-mAbs: There's A Ceiling Here Somewhere Y-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call Transcript Y-mAbs Therapeutics down 18% as Q1 results disappoint Seeking Alpha’s Quant Rating on Y-mAbs T...
Message Board Posts | Y-mAbs Therapeutics Inc. (NASDAQ:YMAB)
Subject | By | Source | When |
---|---|---|---|
$YMAB: WHAT????? | Invest-in-America | investorshub | 04/02/2023 2:50:17 PM |
there she goes | TrendTrade2016 | investorshub | 03/31/2023 2:34:59 PM |
HERE COMES THE 5 DOLLA BREAK | TrendTrade2016 | investorshub | 03/31/2023 2:28:43 PM |
$YMAB TO 5.34 | TrendTrade2016 | investorshub | 03/31/2023 2:21:26 PM |
YMAB...ANOTHER BIO READY TO FLY | TrendTrade2016 | investorshub | 03/31/2023 2:07:20 PM |
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...